Immunohistochemistry Market to Reach USD 5.5 Billion by 2031, Owing to Continuous Advancements in IHC Technology

Discover the dynamic Immunohistochemistry Market, projected to flourish between 2024-2031, driven by rising demand in diagnostic and research applications across hospitals, academic institutions, and CROs worldwide. Explore regional growth and industry trends shaping this vital sector!
[https://www.skyquestt.com/report/immunohistochemistry-market] size was valued at around USD 3.1 billion in 2023 to reach a value of USD 5.5 billion by 2031, at a CAGR of 7.4% over the forecast period (2024-2031). The technology of immunohistochemistry has been revolutionized by automation and integration with machine learning, which is pushing the industry forward. These technological advancements have made the processes of IHC streamlined and efficient to detect diseases fast and accurately. The staining, image processing, and data interpretation processes that have previously been slow and accompanied by human error are automated processes, thus results are higher and human error is lower. Enhanced diagnostic potential for IHC by applying machine learning techniques that enable detection and classification of tissue markers. Moreover, the industry extends further with the development of highly advanced immunohistochemistry solutions. By improved sensitivity, specificity, and multiplexing, these technologies can potentially enable pathologists and researchers to extract out of tissue samples a full and accurate view of cellular data.

Explore Comprehensive Insights into The Immunohistochemistry Market with A Detailed Sample Report: https://www.skyquestt.com/sample-request/immunohistochemistry-market

Streamlining IHC Workflows for Transforming Immunohistochemistry

Automation technologies, such as robotic systems and sophisticated image processing software, are being developed for IHC platforms to enhance productivity, accuracy, and repeatability. This tends to decrease human error and enhance diagnostic performance by allowing fast and consistent investigation into tissue samples. An emerging trend in IHC data processing is the integration of AI and ML algorithms into these platforms, allowing improved quantification and interpretation of staining patterns. The trend towards automation and digitization will transform immunohistochemistry and laboratory procedures in pathology and research labs.

For instance, in March 2023, Aptamer Group announced a new reagent solution called Optimer-Fc specifically for automated immunohistochemistry (IHC) operations. This leading device is supposed to give better probing tools to scientists and diagnosticians so that newly found biomarkers can be explored in research and diagnostics with more efficiency. Optimer-Fc can enhance the accuracy and reliability of studies based on IHC and thus help identify and characterize diseases more effectively by giving superior sensitivity and specificity.

Building a Competitive Edge in Immunohistochemistry

The Immunohistochemistry market is very competitive, with many large competitors in the market. This includes big international companies and regional and smaller local firms. The competition of these businesses is based on so many factors such as product line, new technology innovations, cost, and channels of distribution. The large market participants have invested heavily in R&D, which gives advanced IHC solutions to customers. They expand their product portfolio and strengthen their position in the market. Market participants actively participate in marketing and other promotional activities to create an awareness about their IHC products among customers and increase customer base. The business organizations face tough competition in the market as they compete to answer the growing demand for accurate and reliable diagnostic tools in pathology and research.

Ask for Free Customization: https://www.skyquestt.com/speak-with-analyst/immunohistochemistry-market

Strategic Moves by Key Players

In September 2022, Roche launched the Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody that detects PRAME protein expression in tissue samples acquired from patients suspected to be affected by melanoma.

In March 2022, the CASI Consortium for Analytic Standardization in Immunohistochemistry was established by Boston Cell Standards to improve the validity and reliability of immunohistochemistry patient tests. This collaboration is under the governance of a global panel of scientists and pathologists following an initial fund of USD 2 million provided by the U.S. National Cancer Institute.

In March 2021, Roche developed the DISCOVERY Green HRP chromogen detection kit to further make use of immunohistochemistry multiplexing in cancer studies.

This report covers following segments:

Product

Antibodies (Primary, Secondary)

Clonality (Monoclonal Antibodies, Polyclonal Antibodies)

Reagents (Histological Stains, Blocking Sera and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, Other Reagents (Antigen Retrieval Solutions, Stabilizers, Controls, And Mounting Solutions))

Equipment (Slide-staining Systems, Tissue Processing Systems, Slide Scanners, Other Equipment (Digital Pathology Systems and Histology Equipment, Such as Automated Cover Slippers, Visualization Equipment (Bright-Field, Fluorescence Microscopes), Microtomes, Paraffin Dispensers, Slide Labelers, And Tissue Microarrays))

Kits (Human Immunohistochemistry Kits, Animal Immunohistochemistry Kits)

Application

Diagnostic applications (Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, other diseases (Ophthalmic, Cardiovascular, Dermatological, And Dental Diseases))

Research applications (Drug Development and Testing, Other research applications (Stem Cell Research and Developmental Biology))

Forensic Applications

C. End User

Hospitals & Diagnostic Laboratories

Academic Institutions & Contract Research Organizations (CROs)

Other end users (Pharmaceutical & Biopharma Companies, and Forensic Laboratories)

Immunohistochemistry Market Top Player's Company Profiles:

F. Hoffmann-La Roche Ltd.

Danaher Corporation

Agilent Technologies Inc.

PHC Holdings Corporation

Thermo Fisher Scientific Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Bio-Techne

Becton, Dickinson and Company

Takara Bio Inc.

Enzo Biochem Inc.

Sino Biological, Inc.

Sakura Finetek Japan Co., Ltd.

Cell Signaling Technology, Inc.

BIO SB

Miltenyi Biotec

OriGene Technologies, Inc.

EagleBio

Biocare Medical, LLC

Elabscience Bionovation Inc.

BioGenex

Diagnostic BioSystems Inc.

Histo-Line Laboratories

Rockland Immunochemicals, Inc.

Candor Bioscience GmbH

Genemed Biotechnologies, Inc.

Take Action Now: Secure Your Immunohistochemistry Market Today - https://www.skyquestt.com/buy-now/immunohistochemistry-market

Promising Future for Immunohistochemistry Market

The Immunohistochemistry market has bright prospects. Incidence increases due to chronic diseases and the necessity for individualized drugs has already increased. Further, advancement in diagnostic methods raises growth of this market. Furthermore, with the concepts of precision medicines and targeted medicines, the reliance on IHC tests both for drug development and for patient stratification is further growing.

Read Full Report - https://www.skyquestt.com/report/immunohistochemistry-market

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immunohistochemistry-market-to-reach-usd-55-billion-by-2031-owing-to-continuous-advancements-in-ihc-technology]
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/immunohistochemistry-market



This release was published on openPR.